D
David W. Johnson
Researcher at University of Queensland
Publications - 2880
Citations - 157072
David W. Johnson is an academic researcher from University of Queensland. The author has contributed to research in topics: Peritoneal dialysis & Kidney disease. The author has an hindex of 160, co-authored 2714 publications receiving 140778 citations. Previous affiliations of David W. Johnson include Minnesota Department of Transportation & Open University.
Papers
More filters
Journal ArticleDOI
Core competencies in the science and practice of knowledge translation: description of a Canadian strategic training initiative
Sharon E. Straus,Melissa C. Brouwers,David W. Johnson,John N. Lavis,Sumit R. Majumdar,K Ann McKibbon,Anne E. Sales,Dawn Stacey,Gail Klein,Jeremy M. Grimshaw +9 more
TL;DR: This work has identified core competencies in this field and has developed a series of educational courses and materials for three training streams to meet the capacity demand for KT researchers and practitioners in Canada.
Journal ArticleDOI
ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I – Assessment and Management of Various Cardiovascular Risk Factors
Angela Yee-Moon Wang,K. Scott Brimble,Gillian Brunier,Stephen G Holt,Vivekanand Jha,David W. Johnson,David W. Johnson,Shin Wook Kang,Jeroen P. Kooman,Mark Lambie,Christopher W. McIntyre,Rajnish Mehrotra,Roberto Pecoits-Filho +12 more
TL;DR: This publication forms the first part of the guideline documents and includes recommendations on assessment and management of various cardiovascular risk factors and is intended to serve as a global clinical practice guideline for clinicians who look after PD patients.
Journal ArticleDOI
Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand.
TL;DR: The results of this study suggest that fansidar resistance is prevalent at this camp and should prompt more exhaustive studies of the epidemiology of fansidars resistance in the area.
Journal ArticleDOI
Increasing access to integrated ESKD care as part of universal health coverage
David Harris,Simon J. Davies,Fredric O. Finkelstein,Vivekanand Jha,Vivekanand Jha,Jo-Ann Donner,Georgi Abraham,Aminu K. Bello,Fergus Caskey,Fergus Caskey,Fergus Caskey,Guillermo Garcia Garcia,Paul N. Harden,Brenda R. Hemmelgarn,David W. Johnson,David W. Johnson,David W. Johnson,Nathan W. Levin,Valerie A. Luyckx,Valerie A. Luyckx,Dominique Martin,Mignon McCulloch,Mohammed Rafique Moosa,Philip J. O'Connell,Ikechi G. Okpechi,Roberto Pecoits Filho,Kamal D. Shah,Laura Sola,Charles R. Swanepoel,Marcello Tonelli,Ahmed Twahir,Wim Van Biesen,Cherian Varghese,Chih-Wei Yang,Carlos Zuniga,Ali K. Abu Alfa,Harith M. Aljubori,Mona Alrukhaimi,Sharon Andreoli,Gloria Ashuntantang,Ezequiel Bellorin-Font,Bassam Bernieh,Fuad M. Ibhais,Peter G. Blake,Mark Brown,Edwina A. Brown,Sakarn Bunnag,Tak Mao Chan,Yuqing Chen,Rolando Claure-Del Granado,Stefaan Claus,Allan J. Collins,Cécile Couchoud,Alfonso M. Cueto-Manzano,Brett Cullis,Walter Douthat,Gavin Dreyer,Somchai Eiam-Ong,FU Eke,John Feehally,Mohammad Ghnaimat,Bak Leong Goh,Mohamed H. Hassan,Fan Fan Hou,Kitty J. Jager,Kamyar Kalantar-Zadeh,Rumeyza Kazancioglu,Adeera Levin,Adrian Liew,Marla McKnight,Yewondwassesn Tadesse Mengistu,Rachael L. Morton,Elmi Muller,Fliss E M Murtagh,Saraladevi Naicker,Masaomi Nangaku,Abdou Niang,Gregorio T. Obrador,Shahrzad Ossareh,Jeffrey Perl,Muhibur Rahman,Harun Ur Rashid,Marie Richards,Eric Rondeau,Manisha Sahay,Abdulkarim Saleh,Daniel Schneditz,Irma Tchokhonelidze,Vladimir Tesar,Michele Trask,Kriang Tungsanga,Tushar J. Vachharajani,Rachael C. Walker,Robert J. Walker,Anthony J.O. Were,Qiang Yao,Karen Yeates,Xueqing Yu,Elena Zakharova,Alexander Zemchenkov,Ming-Hui Zhao +100 more
TL;DR: The purpose was to develop a strategic plan to improve worldwide access to integrated ESKD care, by identifying and prioritizing key activities across 8 themes, and an overarching performance framework were developed for each theme.
Journal ArticleDOI
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
Tina Bagratuni,Ping Wu,David Gonzalez de Castro,Emma L. Davenport,Nicholas J. Dickens,Brian A Walker,Kevin Boyd,David W. Johnson,Walter M Gregory,Gareth J. Morgan,Faith E. Davies +10 more
TL;DR: It is shown that IRE1alpha and X BP1 are highly expressed and that patients with low XBP1s/u ratios have a significantly better overall survival, and the beneficial therapeutic effects of thalidomide in patients withLow XBP 1s/U ratios are shown.